Aurobindo Pharma board to review Q2, half-year financials November 5

Aurobindo Pharma Limited has announced that its board of directors will convene on Wednesday, November 5, 2025. The primary agenda for this meeting is to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half-year period ending September 30, 2025. This intimation was made on October 24, 2025.

The company also provided an update regarding its trading window. Following an earlier communication dated September 24, 2025, the trading window, which closed on July 1, 2025, will remain shut until November 7, 2025. It is scheduled to reopen on November 8, 2025, subsequent to the declaration of the financial results. This closure covers the period 48 hours prior to the results announcement.